Alamar Biosciences, Inc. (ALMR)
NASDAQ: ALMR · Real-Time Price · USD
27.11
+0.04 (0.15%)
At close: Aug 4, 2026, 4:00 PM EDT
27.89
+0.78 (2.89%)
After-hours: Aug 4, 2026, 4:26 PM EDT
Alamar Biosciences Revenue
Alamar Biosciences had revenue of $26.04M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $87.16M. In the year 2025, Alamar Biosciences had annual revenue of $74.21M with 195.17% growth.
Revenue (ttm)
$87.16M
Revenue Growth
+195.17%
P/S Ratio
20.91
Revenue / Employee
$392,590
Employees
222
Market Cap
1.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 74.21M | 49.07M | 195.17% |
| Dec 31, 2024 | 25.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ALMR News
- 7 days ago - Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome - GlobeNewsWire
- 20 days ago - Alamar Biosciences price target raised to $34 from $30 at TD Cowen - TheFly
- 21 days ago - Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 - GlobeNewsWire
- 22 days ago - Alamar teams with research universities to launch proteomics initiatives - TheFly
- 22 days ago - Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases - GlobeNewsWire
- 25 days ago - Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling - GlobeNewsWire
- 4 weeks ago - Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research - GlobeNewsWire
- 2 months ago - Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics - GlobeNewsWire